Always at the forefront of the dynamic patient-derived xenograft (PDX) market, Champions Oncology has emerged as a respected key opinion leader on the utilization and benefits of PDX models in oncology drug development.

SITC 2019

New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2019

AACR 2019

EORTC 2018

SITC 2018

AACR 2018

EORTC 2017

AACR 2017

EORTC 2016

EACR 2016

EORTC 2015

AACR 2015

AACR 2014

EORTC 2014